Universal Time: 08:49  |  Local Time: 08:49 (0h GMT)
Select your timezone:

Sun Sep 13

23:30 - 00:15 Oral Abstracts Session: Kidney Transplantation: Biomarkers
210.1 Diagnostic tests for delayed graft function: A systematic review
Christina Lai, Australia
210.2 Integrative analysis of prognostic biomarkers for acute rejection in kidney transplant recipients
Yue Cao, Australia
210.3 Assessment of the usefulness of acute rejection specific transcriptomic signatures in a prospective kidney transplantation cohort
Su Woong Jung, Korea
210.4 The clinical utility of preformed C1q-binding donor-specific HLA antibodies in kidney transplantation
Sua Lee, Korea
23:30 - 00:15 Oral Abstracts Session: Innate and Adaptive Immunity
211.1 Gasdermin-D mutation is protective against renal ischemia reperfusion injury
Jennifer Li, Australia
211.5 (P-2.74 in Journal) Oral administration of nano-sized silicon particles attenuates oxidative stress and ischemia-reperfusion injury in a rat model: A novel hydrogen administration method
Masataka Kawamura, Japan
211.3 Modulation of the IL-33/ST2 axis for regulatory T cell therapy in transplantation
Kento Kawai, United Kingdom
211.4 Development of fully differentiated pancreatic organoids from hiPSCs for type 1 diabetes cell therapy
Giuseppe Pettinato, United States

Mon Sep 14

00:15 - 02:00 State-of-the-Art Session: Tissue-Resident Lymphocytes
220.1 Formation and plasticity of tissue resident memory populations in human allografts revealed by single cell analysis and serial TCR sequencing
Megan Sykes, United States
220.2 Antigen presentation by tissue resident APC
Adrian E. Morelli, United States
220.3 Reshaping T cell memory with lymphoablation
Anna Valujskikh, United States
07:30 - 08:15 Oral Abstracts Session: Immune Regulation and Outcomes
251.2 Discovery of pMHC epitopes for directly alloreactive T cells
Eric Taeyoung ES Son, Australia
251.3 The Prediction of Kidney Allograft Acute Rejection Based on Recipient Peripheral Blood Whole Transcriptome Profiling and Three mRNA Molecular Signatures
Liao Minxue, People's Republic of China
251.4 Myeloid derived suppressor cells (MDSC) in kidney recipients: Identification of CD25+eMDSC, and augmentation of monocytic-MDSC early after transplantation in patients later developing cancer
Alberto Utrero-Rico, Spain
251.1 Elucidating the role of hypoxia in regulatory T cell function
Marie Sion, United Kingdom
08:15 - 10:00 State-of-the-Art Session: Banff 2019 Update for Allograft Rejection
262.1 Liver (morphology)
Andrew Clouston, Australia
262.4 Kidney (molecular)
Carmen Lefaucheur, France
262.3 Kidney (morphology)
Hyeon Joo Jeong, Korea
262.2 Liver (molecular phenotyping)
Alberto Sanchez-Fueyo, United Kingdom
14:30 - 15:15 Oral Abstracts Session: Biomarkers and Omics
281.3 Single cell transcriptomic analysis for a better understanding of human CD8+ regulatory T cells
Céline Serazin, France
281.1 Transplantation of older organs transfers senescence
Jasper Iske, Germany
281.5 (P-2.125 in Journal) TCR repertoire sequencing of total T cells and circulating follicular helper T cells in kidney transplant recipients
Patricia Almendro Vázquez, Spain
281.2 Diagnosis of kidney transplant rejection by tracking donor-reactive T-cell clones in the post-transplant biopsy, blood and urine samples
Joseph R. Leventhal, United States
15:15 - 17:00 State-of-the-Art Session: Kidney Transplantation: The borg and beyond
290.1 The repair shop: Our current opportunities in improving the quality of kidneys
Sarah Hosgood, United Kingdom
290.2 A reality check - kidney organoids: What to expect in the next 10 years
Benjamin Humphreys, United States
290.3 Artificial intelligence in renal transplantation: core concepts, examples, limits and perspectives
Olivier Niel, Luxembourg
15:15 - 17:00 State-of-the-Art Session: Social Media for Scientists
291.3 Impact of social media on research dissemination
Carla C. Baan, Netherlands
291.1 Introduction and creating networks
Frank JMF Dor, United Kingdom
291.2 Healthcare and patient education
Macey L. Henderson, United States
23:30 - 00:15 Oral Abstracts Session: Kidney Transplantation: Predicting allograft survival
310.4 A personalised prediction model for allograft survival after kidney transplantation
Yunwei Zhang, Australia
310.2 Simultaneously detection of ddcfDNA in plasma and urine assist to determine the type of rejection in renal transplant patients
Dongrui Cheng, People's Republic of China
310.1 Advanced tertiary lymphoid tissues in protocol biopsies predict progressive graft dysfunction in kidney transplant recipients
Yu Ho Lee, Korea
310.3 Near-single-cell proteomicsprofiling of the proximal tubular and glomerulus of the normal human kidney
Tara Sigdel, United States
23:30 - 00:15 Oral Abstracts Session: Histocompatibility and Cancer Complications
314.1 Do we predict mismatches that induce de novo DSA or do we predict the ones that do not?
Vadim Jucaud, United States
314.2 HLA molecular mismatch analysis in patients receiving kidney and the hematopoietic stem / facilitating cell induction protocol
Anat Tambur, United States
314.3 Cancer risk in solid organ transplant recipients: A systematic review and meta-analysis
Zhenyu Huo, People's Republic of China
314.5 (P-11.126 in Journal) Relative survival in kidney transplant recipients with de-novo cancers vs non-transplant cancer patients: A population study 1980-2016
Nicole Louise De La Mata, Australia

Tue Sep 15

07:30 - 08:15 Oral Abstracts Session: Kidney Transplantation: Ischemia/reperfusion injury and long-term graft outcomes
350.1 Role of IL-6 and IL-17 mediated inflammation amplifier loop in Chronic Antibody-Mediated Rejection (CABMR)
Mantabya Kumar Singh, India
350.2 A biocompatible nanoparticle-based approach to inhibiting renal ischemia reperfusion injury in mice by blocking thrombospondin-1 activity
Tianmeng Sun, People's Republic of China
350.4 Impact of acute kidney injury on graft outcomes in deceased donor kidney transplantation: A nationwide registry-based matched cohort study in Korea
Jane Ha, Korea
350.5 (P-2.81 in Journal) A point mutation of SHROOM3 promotes CD206+ macrophage infiltration and kidney fibrosis after ischemia-reperfusion injury
Tianfeng Tang, People's Republic of China
08:15 - 10:00 State-of-the-Art Session: The Future is Now… Immune Regulation in Transplantation
360.1 The Regulation of Immune Tolerance by FOXP3 - basic
Ling Lu, People's Republic of China
360.2 Intragraft immune regulation protects transplants under sub-therapeutic immunosuppression
Paloma Riquelme, Germany
James Alexander Hutchinson, Germany
360.3 Clinical experience of Treg therapy
Fadi Issa, United Kingdom
14:30 - 15:15 Oral Abstracts Session: Kidney Transplantation: Antibody-mediated rejection and composite end points
380.1 Anti-IL-6 antibody clazakizumab in late antibody-mediated rejection – Molecular rebound phenomena under IL-6 blockade?
Anita Borski, Austria
380.4 Analyzing causes for death-censored allograft failure in kidney transplant recipients
Manuel Mayrdorfer, Germany
380.2 Clazakizumab (Anti-IL-6 Monoclonal) treatment of patients with chronic & active antibody-mediated rejection post-kidney transplantation (NCT03380377)
Stanley Jordan, United States
380.3 Analyzing a pragmatic composite endpoint for 1-year kidney transplant outcomes: Patient loss, graft loss and eGFR less than 30. Results from NSQIP Transplant beta phase
Dominic Amara, United States
14:30 - 15:15 Oral Abstracts Session: Immune Regulation and Tolerance I
381.4 Single cell immune profiling of human intestinal allografts reveals heterogeneity and alloreactivity of recipient resident memory T cells in association with graft outcomes
Jianing Fu, United States
381.1 Treg use the PD-1-PD-L1 axis for lymphatic transendothelial migration
Wenji Piao, United States
381.2 Donor liver plasmacytoid dendritic cells promote effector T cell exhaustion and augment Treg responses in mouse spontaneous liver transplant tolerance
Ryosuke Nakano, United States
381.3 Lymph node stromal laminin alpha 5 regulates adaptive immunity
Lushen Li, United States
15:15 - 17:00 State-of-the-Art Session: Novel Insights in Allorecognition
391.3 Non-HLA allorecognition and graft loss
Roman Reindl-Schwaighofer, Austria
391.2 T-cell allorecognition
Gavin Pettigrew, United Kingdom
391.1 Innate allorecognition
Fadi G. Lakkis, United States
23:30 - 00:15 Oral Abstracts Session: Kidney Transplantation: Novel approaches to monitoring
410.1 (P-11.189 in the Journal) Reactivation of murine polyomavirus replication by renal ischemia-reperfusion injury and immunosuppression
Gang Huang, People's Republic of China
410.3 Analysis of the difference of the monitoring results of TCR high variable area in renal transplant recipients after treatment with different immune induction schemes
Tian Puxun, People's Republic of China
410.4 Novel human kidney cell subsets identified by Mux-Seq
Tara Sigdel, United States

Wed Sep 16

07:30 - 08:15 Oral Abstracts Session: Kidney Transplantation: Living donation and long-term follow-up
450.2 (P-11.107 in Journal) Impact of single centre 440 kidney exchange transplantation over 20 years to increase living donor pool in India: A cohort study
Harshit M Patel, India
450.3 Telemedicine clinic for renal transplant patients during COVID-19 pandemic
Fatima AlKindi, United Arab Emirates
450.4 Parameters affecting estimated glomerular filtration rate and developing hypertension after donor nephrectomy
Zeynep Kendi Çelebi, Turkey
07:30 - 08:15 Oral Abstracts Session: Immune Regulation and Tolerance II
451.3 PD-L1 / PD-1 interactions are critical for tolerance induction in primed skin graft recipients following liver-directed MHC class I gene transfer
Mario L Leong, Australia
451.2 Identification and isolation of human HLADR+ CD27+ Treg as xeno-antigen Treg subset for xenotransplantation
Xiaoqian Ma, People's Republic of China
451.1 Transient antibody targeting of CD45RC to prevent the development of acute graft versus host diseases
Carole Guillonneau, France
451.4 CTLA-4-Ig prolongs graft survival specifically in young but not in old recipients
Jasper Iske, Germany
08:15 - 10:00 State-of-the-Art Session: A Kidney for Life: A goal for all practitioners
460.1 A look at the long-term surviving patient: What makes them so exceptional?
Germaine Wong, Australia
460.2 Chronic allograft injury: CAN CAN be fixed?
Dirk R. J. Kuypers, Belgium
460.3 Anti-body mediated rejection: Consensus on treatment?
Roslyn B Mannon, United States
14:30 - 15:15 Oral Abstracts Session: Kidney Transplantation: Desensitization and other complications
480.4 Rapamycin prevents interstitial fibrosis through decreasing peritubular capillary (PTC) VEGF expression and angiogenesis while inducing glomerular sclerosis and proteinuria through decreasing glomerular VEGF expression
Binnaz Handan Ozdemir, Turkey
480.1 Clazakizumab® (Anti-IL-6) for desensitization of highly-HLA sensitized patients awaiting kidney transplant (NCT03380962)
Ashley Vo, United States
480.2 Clazakizumab (anti-IL-6) induces FoxP3+ Tregs in highly HLA sensitized patients receiving HLAi kidney transplantation (NCT03380962)
Stanley Jordan, United States
480.3 CD8+ T cell senescence is a distinct immunological state that identifies long-term renal transplant recipients at increased risk of future malignancy
Matt J Bottomley DPhil, United Kingdom
15:15 - 17:00 State-of-the-Art Session: Sex as an Immunological Variable
490.3 The role of the X chromosome in organ transplantation
Anette Melk, Germany
490.1 Improved renal ischemia tolerance in females influences kidney transplantation outcomes
Matthew Levine, United States
490.2 Sex as a biological variable
Stefan G. Tullius, United States


Poster Session: Basic and Translational Sciences
P-2.02 B-cell depletion with anti-CD20 mAb exacerbates anti-donor CD4 positive T-Cell responses in highly sensitized transplant model
Asuka Tanaka, Japan
P-2.03 Noninvasive genotyping of donor’s HLA in kidney transplant patients by target capture sequencing
Liu Feng, People's Republic of China
P-2.04 Clinical significance of pretransplant donor-specific HLA antibodies in kidney transplant recipients of hispanic population
Idalia Parra-Avila, Mexico
P-2.05 Female complexity: High ‘natural’ ABO anti-A antibodies and IgG class switch in female vs male mice
Bushra Anjum, Canada
P-2.10 Immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma patients as a basis for early vaccination with T-cell dependent vaccines
Igor Stoma, Belarus
P-2.11 Imbalance favouring follicular helper T cells over IL10+ regulatory B cells is detrimental for the renal allograft
Alberto Utrero-Rico, Spain
P-2.13 Extracellular vesicles from urine as biomarkers of kidney allograft injury: optimization of extracellular vesicle isolation and characterization
Ivana Sedej, Slovenia
P-2.14 Establishment of early warning model of acute rejection in combination with HLA-G 14-bp gene polymorphism, serum KIM-1and OPN
Zhankui Jin, People's Republic of China
P-2.15 Immunosuppression affects circulating follicular regulatory T cells in kidney transplant recipients
Carla C. Baan, Netherlands
P-2.16 The use of dd-cfDNA as a predictive tool for future proteinuria
Thierry Viard, United States
P-2.17 Characterization of an integrative prognostic score for US patients taken from the DART study
Thierry Viard, United States
P-2.18 dd-cfDNA as a risk factor for initiating de-novo donor specific antibodies in heart transplantation
Thierry Viard, United States
P-2.19 Factors influencing background cell-free DNA levels: Implications for donor derived cell-free DNA assessment in transplant patients
Trudy McKanna, United States
P-2.20 Anti-rejection therapy does not eliminate donor-reactive IFN-γ and IL-21 producing cells
Nicole M. van Besouw, Netherlands
P-2.22 Use of dd-cfDNA as a surrogate marker of injury following hypothermic machine perfusion
Thierry Viard, United States
P-2.23 Establishment of early diagnostic model of acute rejection in combination with IL-2, IL-6, TNF-α and IFN-γ
Zhankui Jin, People's Republic of China
P-2.24 Incidence and risk factors of new onset diabetes after solid organ transplantation: Baskent University experience
Didem Turgut, Turkey
P-2.25 Value of dd-cfDNA when considering recipient ethnicity to further to help risk stratify transplant recipients
Thierry Viard, United States
P-2.26 Long-lasting effects of anti-rejection therapy on natural antibodies and alloreactive T cells in kidney transplant patients
Nicole M. van Besouw, Netherlands
P-2.27 Podocyte-specific urinary extracellular vesicles: A novel biomarker for recurrent primary focal segmental glomerulosclerosis after kidney transplantation
Hien Lau, United States
P-2.29 The relationship between myocardial fibrosis and plasma level of galectin-3 in heart transplant recipients underwent acute rejection
Rivada Kurabekova, Russian Federation
P-2.30 Do the blood groups and HLA types have a role in end stage chronic renal failure pathogenesis? A comparative retrospective single-center study
Ugur Musabak, Turkey
P-2.31 Immune signs of accommodation in kidney transplant recipients
Maciej Zieliński, Poland
P-2.32 Spot urine protein excretion during the first year after kidney transplantation associates with allograft rejection phenotype at 1-year surveillance biopsies: An observational national-cohort study
Miha Arnol, Slovenia
P-2.33 The utility of QuantiFERON monitoring based assay in assessing clinical events among kidney transplant recipients
Maisarah Jalalonmuhali, Malaysia
P-2.36 Early post-transplant infusion of ex vivo-expanded autologous polyclonal regulatory T cells (Treg) prolongs kidney allograft survival in nonlymphodepleted, CTLA4Ig-treated rhesus monkeys<span class="uk-margin-small-right" uk-icon="video-camera"></span>
Kazuki Sasaki, United States
P-2.37 IL-21 as a new target for immunosuppressive therapies
Carla C. Baan, Netherlands
P-2.38 The small-molecule BCL6-inhibitor 79-6 suppresses follicular T helper cell differentiation and plasma blast formation
Rens Kraaijeveld, Netherlands
P-2.39 Intra-lymph node delivery of macroparticles loaded with rapamycin in non-human primates
Zahra Habibabady, United States
P-2.40 Clinical-experimental experience with rapamycin in visceral transplantation
Javier Serradilla, Spain
P-2.41 The effects of a novel drug, PQA 18, on small intestinal transplantation
Tasuku Kodama, Japan
P-2.45 Cyclic helix B peptide ameliorates renal fibrosis induced by unilateral ureter obstruction via inhibiting NLRP3 pathway
Cheng Yang, People's Republic of China
P-2.47 The preventive effect of sirolimus on ureteral stricture formation
Sanem Cimen, Turkey
P-2.49 Primate tolerance model demonstrates longer kidney graft survival with the administration of polyclonal ex-vivo expanded Tregs
Karina Bruestle, United States
P-2.50 IL-4 regulates the secretion of IL-10 by human B cells
Griffith Perkins, Australia
P-2.51 Immunomodulation with SA-PDL1 protein on pancreatic islets promotes indefinite graft survival in allogeneic recipients
Esma ESY Yolcu, United States
P-2.53 Anti-IL-6 antibody reduces endothelial mediated pro-inflammatory responses and after binding of HLA-specific DSA to endothelial cells
Nuala Mooney, France
P-2.54 Preclinical study for tolerance induction to liver allografts with rapid immunosuppression withdrawal in Cynomolgus monkeys
Hiroshi Sakai, United States
P-2.55 Strong engagement of Cd137 suppresses graft-versus-host disease through dendritic cells
Sang Jun Park, Korea
P-2.59 The requirement of thymic irradiation for induction of mixed chimerism and renal allograft tolerance in non-human primates
Takayuki Hirose, United States
P-2.60 Experimental evidence on the role of the spleen in graft versus host disease after visceral transplantation
Pablo Stringa, Argentina
P-2.61 Comparison between vitamin C-treated induced-regulatory T cells and conventional induced-regulatory T cells in suppressing heart allograft rejection in either vitamin C-sufficient or vitamin C-deficient conditions
Juhee Hwang, Korea
P-2.62 Advantages of rhesus macaques in a tolerance model for combined bone marrow and kidney transplantation
Karina Bruestle, United States
P-2.63 siRNA gene knockdown with functionalised porous silicon nanoparticles
Sebastian O Stead, Australia
P-2.66 Class II HLA eplet mismatch is related to anti-donor CD4+ T cell response and de novo donor-specific antibody development in kidney transplantation recipient
Hiroaki Yamane, Japan
P-2.70 Changes in phenotype of human CD4+CD25+CD127lo Treg subpopulations after culture with rIL-2 and alloantigen
Nirupama D Verma, Australia
P-2.73 Mobilization of mast cells and regulatory t-cells by tetrahydrobiopterin is associated with prolonged allograft survival
Manuel Maglione, Austria
P-2.82 INT 767 – A novel dual farnesoid-X receptor (FXR) and takeda G-protein-coupled receptor-5 (TGR5) agonist attenuates intestinal ischemia reperfusion injury
Emilio Canovai, Belgium
P-2.84 High-mobility group box 1 protein antagonizes the immunosuppressive capacity and therapeutic effect of mesenchymal stem cells in acute kidney injury
Cheng Yang, People's Republic of China
P-2.85 Mesenchymal stem cell-derived exosomes suppress of NLRP3 inflammasome activation to enhance anti-anoxic ability of porcine islets
Wei Nie, People's Republic of China
P-2.95 A novel rodent model of severe renal ischemia reperfusion injury that better mimics the renal transplant recipient
Ryan Ghita, United Kingdom
P-2.96 Ischemic preconditioning ameliorates renal ischemia-reperfusion injury through activating the Nrf2/HO-1 pathway enhanced autophagy in mice
Jeongkye Hwang, Korea
P-2.99 In-depth assessment of ischemia/reperfusion injury in a murine model of hindlimb transplantation
Franka Messner, Austria
P-2.103 Ischemic preconditioning attenuates renal ischemia-reperfusion injury by TLR4 suppression and eNOS activation
Jeongkye Hwang, Korea
P-2.104 The impact of oxygen free radical scavenger on acute rejection in a histocompatible miniature swine model
Philipp Tratnig-Frankl, United States
P-2.105 The tissue Common Response Module (tCRM) score provides a quantitative objective biopsy score to assess the severity of pancreas transplant rejection
Yvonne Kelly, United States
P-2.107 Increased level of serum cholesterol and apoptosis together induces the development of liver fibrosis and early allograft loss
Binnaz Handan Ozdemir, Turkey
P-2.108 Analyzing interactions between donor endothelium and recipient blood under flow conditions in vitro
Margaret Connolly, United States
P-2.113 Influence of β-Catenin on the proliferation of vascular smooth muscle cells and the development of cardiac allograft vasculopathy in mice
Christian Heim, Germany
P-2.115 Recipient bone marrow Treg; major players in transplant tolerance
Amy Prosser, Australia
P-2.116 High-fibre diet reduces transplant-associated dysbiosis and improves renal allograft survival in a murine model of kidney allograft rejection
Julian Singer, Australia
P-2.119 Gut microbiome dynamics over a course of kidney transplantation: Preliminary results of a pilot study
Igor Stoma, Belarus
P-2.121 Characterization of donor and recipient myeloid cells following congenic and allogeneic liver transplantation
Sarah J Dart, Australia
P-2.122 Preparation of transplantable acellular scleral graft using porcine eye
Kyungmee Park, Korea
P-2.123 Preparation of ultra-thin descemet's membrane graft using decellularized porcine cornea
Kyungmee Park, Korea
P-2.124 NK cell exhaustion facilitates tumor recurrence after liver transplantation via the TLR4 / HLA-E signaling pathway
Xinxiang Yang, People's Republic of China
P-2.126 Assessment of HLA typing performance of Korea Biobank Array for transplantation genome-wide association study in Koreans
Young Jin Kim, Korea
P-2.129 A genome-wide association study identified genetic loci for end-stage renal disease in the Korean population
Young Jin Kim, Korea
P-2.130 Vascular endothelial growth factor (vegf) 936 C/T gene polymorphism in renal transplant recipients: Association with graft rejection and final graft outcome
Manzoor Parry, India
P-2.131 Lymphotoxin beta receptor regulates Treg stability, migration, and function
Vikas Saxena, United States
P-2.133 Liver tissue-resident lymphocytes are significantly heterogeneous, and the original repertoire is not recreated by infiltrating recipient cells
Amy Prosser, Australia
P-2.137 Ischemic and perfused kidney treated with non-cultured adipose-derived regenerative cells increase the immune and regulatory transcriptome
Ryan Ghita, United Kingdom
Poster Session: Histocompatibility
P-7.07 Assessment of ABO-histocompatibility: Modernizing ABO antibody detection tools for use in transplantation
Anne Halpin, Canada
P-7.10 Can epitope matching outmatch traditional HLA matching?
Christian Unterrainer, Germany
P-7.04 Prospective de novo DSA monitoring in renal transplant patients
Efstratios Kasimatis, Greece
P-7.05 Angiotensin II Type 1 Receptor Antibodies: Risk for rejection and impaired graft function
Angeliki G. Vittoraki, Greece
P-7.14 Tregs monitoring before and after renal transplantation
Efstratios Kasimatis, Greece
P-7.06 Impact of delayed graft function on highly sensitized patients in deceased donor kidney transplantation
Seong Gyu Kim, Korea
P-7.11 Predictability of eplet mismatch to acute rejection in low level HLA antigen mismatched kidney transplantation: Validation analysis of Korean Organ Transplantation Registry (KOTRY) data
Jong Cheol Jeong, Korea
P-7.12 Evaluation of a novel ultra-high-resolution assay and analytic software for next generation sequencing based genotyping of 11 human leukocyte antigen loci
P-7.02 Medium to long term impact of pre transplant DSA on allograft outcomes in deceased donors transplants
Muhammad A Khurram, United Kingdom
P-7.08 Impact of induction regimen, human leukocyte antigen mismatches and steroid maintenance on recipient and graft survival with different glomerulonephridities
Samy M Riad, United States
Poster Session: Kidney
P-11.03 Anti-abo antibody- versus anti-hla antibody-induced antibody mediated rejection in abo-incompatible kidney transplant patients: Relative incidence and phenotype difference
Sung-Hyun Son, Korea
P-11.05 Individualized preconditioning for ABO incompatible living donor kidney transplantation: An initial report of 48 cases from China
Xianding Wang, People's Republic of China
P-11.06 Comparative study of ATG vs ATG-F (Grafalon) as an induction agent in ABO incompatible kidney transplantation
Ravi Kumar Singh, India
P-11.10 Hypercholesterolemia (HC) increases the risk of acute rejection (AR) and leads to chronic rejection (CR) through decreasing endothelial cell surface antigens and increasing both epithelial-to-mesenchymal transition (EMT) and endothelial-to-mesenchymal transition (EndoMT)
Binnaz Handan Ozdemir, Turkey
P-11.12 Factors predicting poor graft function at 1 year after kidney transplantation from deceased donors with acute kidney injury: an analysis of Korean Organ Transplant Registry database
Jane Ha, Korea
P-11.13 Prophylactic treatment with antioxidant nanoparticles attenuate ischemia/reperfusion injury in BALB/c mice
Se-Hee Yoon, Korea
P-11.14 Role of diltiazem in short-term outcome of live related renal transplant hypertensive recipients with non-surgical delayed graft function
Shahzad Alam, India
P-11.15 Incidence, risk factors & patient outcomes of acute kidney injury in patients undergoing living donor liver transplant- A prospective single centre study
Abhyudaysingh Rana, India
P-11.17 Outcomes of deceased donor kidney transplantation using kidneys from donors with acute kidney injury
Kyeongdeok Kim, Korea
P-11.18 Tubulo-Interstitial Nephritis in Graft Kidney Transplant Post Azathioprine Introduction
Salima Awadh Al alawi, Oman
P-11.19 Diabetes mellitus is a risk of AKI incidence in liver transplantation patients
Yujia Wang, People's Republic of China
P-11.20 Cardiovascular outcomes of rapamycin-based immunosuppression in kidney transplant recipients: A single center retrospective study
Sojung Yoon BE, Korea
P-11.23 Should be use kidneys of KDPI higher than 85 percentage for older recipients?
Maria del Carmen Rial, Argentina
P-11.26 The current status and predictors of exercise in kidney transplant recipients: A prospective study using the Health Action Process Approach
shujing hu, Hong Kong
P-11.29 Glomerular deposits of Von Willebrand factor (vWF) and loss of endothelial cell surface antigens on peritubular capillaries (PTCs) showed a strong association with worse graft outcome in recipients with antibody-mediated rejection (ABMR)
Binnaz Handan Ozdemir, Turkey
P-11.33 Detection of donor-derived cell-free DNA: Non-invasive prediction of silent antibody-mediated rejection in donor-specific antibody-positive renal allograft recipients
Markus Wahrmann, Austria
P-11.35 Impact of low dose donor specific anti-HLA antibodies between living donor versus deceased donor kidney transplantation
Seong Gyu Kim, Korea
P-11.36 Combined impact of pre-sensitization and delayed graft function on allograft rejection in deceased donor kidney transplantation: Nationwide cohort study
Hanbi Lee, Korea
P-11.39 The influence of the donor kidney weight to recipient body weight on long-term renal graft outcomes
Seok Jeong Yang, Korea
P-11.40 A proof of concept study for [18F]-sodium fluoride imaging of nephrocalcinosis in donor kidneys and explanted renal allografts
Stan Benjamens, Netherlands
P-11.43 Urinary beta-2-microglobulin as a biomarker for chronic allograft injury and rapid renal function decline in kidney transplant recipients
Hee Jung Jeon, Korea
P-11.47 Inferior outcomes of basiliximab compared to anti-thymocyte globulin induction therapy in kidney transplantation with weak pretransplant donor specific anti-HLA antibody
Hyunmin Ko, Korea
P-11.52 Kidney transplantation from HBsAg+ living donors to HBsAg- recipients: Clinical outcomes at a high-volume center in China
Xianding Wang, People's Republic of China
P-11.53 Cytomegaloviurs-Associated Hemophagocytic Syndrome Diagnosed by Liver Biopsy in a Kidney Transplant Recipient: A case report
Eun Ji Choi, Korea
P-11.54 Lymphocyte subset test as a determinant of Cytomegalovirus prophylaxis in renal transplant recipients with anti-thymocyte globulin induction therapy
Mihyeong Kim, Korea
P-11.55 Differential impact of allograft rejection on kidney transplant patients with BKV infection
Ji Won Min, Korea
P-11.56 Changing severity of Dengue infection in renal transplant recipients: “Unpredictable and lethal”
Harshit M Patel, India
P-11.59 Cytomegalovirus infection after kidney transplantation with pre-emptive strategy: A single-center retrospective cohort study
Chumpol Santisiripat MD, Thailand
P-11.62 Urinary tract infections in renal transplant recipients in three years
Cigdem Erol, Turkey
P-11.63 Pre-kidney transplant latent tuberculosis infection screening and posttransplant active tuberculosis
Gisele Meinerz, Brazil
P-11.65 Emphysematous pyelonephritis in renal transplant recipient
Marisa M Cobos, Argentina
P-11.67 Beyond death and graft survival: Understanding 30-day readmission rates and extended length of stay after kidney transplantation. Results from the NSQIP Transplant beta phase
Dominic Amara, United States
P-11.68 Pre-transplant HLA antibodies and delayed graft function in the current era of kidney transplantation
Caner Suesal, Germany
P-11.69 Aggravation of fibrin deposition and microthrombus formation within the graft during kidney transplantation
Tamar AJ van den Berg, Netherlands
P-11.70 Effect of cold, warm, and composite ischaemic times on one year graft function
Christopher Seet, United Kingdom
P-11.72 CHAIR Score: A novel risk stratification in transplant renal artery stenosis
Xiangyong Tian, People's Republic of China
P-11.75 Abdominal aorta calcification prior to kidney transplantation: The association with patient and graft survival
Stan Benjamens, Netherlands
P-11.76 Review of efficacy and short term safety of sodium-glucose cotransporter 2 (SGLT2) inhibitors use in diabetic renal transplant recipients
Fatima AlKindi, United Arab Emirates
P-11.78 Surgical complications after pediatric kidney transplantation
Aydincan Akdur, Turkey
P-11.79 Co-infection CMV/BK in kidney transplant recipients
Luis Roberto Leon, Argentina
P-11.80 The efficacy of low-dose aspirin in preventing transplant renal artery stenosis (TRAS): A single-center study
Xiangyong Tian, People's Republic of China
P-11.81 Using the Clavien-Dindo classification to identify risk factors in kidney transplantation
Christopher Seet, United Kingdom
P-11.83 Risk factors of recurrence of vesicoureteral reflux after endoscopic treatment after kidney transplantation
Pai Yen Pan, Taiwan
P-11.84 Beware the band adhesion: An unexpected cause of small bowel obstruction following intraperitoneal kidney transplantation
David Tovmassian, Australia
P-11.86 Assessment of neuropathy among renal transplant recipients with post-transplant diabetes mellitus: Kuwait experience
Osama Gheith, Kuwait
P-11.89 Is it possible to prevent reperfusion ischemic injury and DGF (delayed graft function) in kidney allograft? How?
Afshar Zomorrodi, Iran (Islamic Republic of)
P-11.90 Timely surgical intervention for ureteric complications ensures adequate graft function in renal transplantation: A 10-year review
Joseph S Jaya, Australia
P-11.92 Implementation of increased viral risk donor waiting list for pre-consented waitlisted recipients in Victoria, Australia
Nina Seng, Australia
P-11.94 Retrospective analysis of the Kidney Donor Profile Index (KDPI) with patient and graft survival at 5 years post transplantation 
Nasly G Patino-Jaramillo MD, Colombia
P-11.96 Impact of donor cardiopulmonary resuscitation on long-term allograft outcome after deceased donor kidney transplantation in Thailand
Thawin Srinutta, Thailand
P-11.101 The donor factors related with delayed graft function after deceased donor kidney transplantation
Woo Yeong Park, Korea
P-11.102 Donor difference is an important factor to accelerate the implementation of enhanced recovery after surgery (ERAS) in renal transplantation
Tian Puxun, People's Republic of China
P-11.103 Effect of recipient and donor age in deceased donor kidney transplantation in Japan
Yuki Nakagawa, Japan
P-11.105 Outcome of dual kidney transplantation from marginal deceased kidney donor
tarun kumar saha, India
P-11.106 Fully robotic live donor nephrectomy and open implantation in recipients: Does right or left kidney really matter?
Amit Sharma, United States
P-11.110 Comparison of outcomes between open and robot assisted kidney transplant in paediatric population-initial results
Anant Kumar, India
P-11.111 Non-simultaneous kidney exchange cycles in resource restricted countries without non-directed donation
Hari Shankar Meshram, India
P-11.112 Donor and recipient outcomes of retroperitoneal laparoscopic donor nephrectomy in obese versus non obese donors: A prospective study
P-11.113 ATG- F (Grafalon) vs Thymoglobulin( r ATG ) as an induction agent in living donor renal transplant: A retrospective single centre experience
Abhyudaysingh Rana, India
P-11.114 Comparison of clinical outcomes of living donor kidney transplantation in female recipients with birth history according to the relation to a donor
Sung Shin, Korea
P-11.116 AI navigation system for living donor surgery: seven process classification of laparoscopic nephrectomy by deep learning
Masato Nishihara, Japan
P-11.117 Long term results of living donor kidney transplantation
Aydincan Akdur, Turkey
P-11.118 Longest single centre kidney exchange transplant chain of 10 donor-recipients pairs in India.
P-11.119 Comparative analysis of donor and recipient outcomes of laparoscopic vs. open donor nephrectomy for allografts with multiple renal vessels
Dinno Francis A Mendiola, Philippines
P-11.121 Outcome of renal transplantation in Alport's syndrome: A single-center experience.
Harshit M Patel, India
P-11.131 The Korean Organ Transplantation Registry (KOTRY): First official kidney transplantation report
Tai Yeon Koo, Korea
P-11.132 Association between IPV and chronic CNI toxicity with genetic analysis in kidney transplantation
hyo kee kim, Korea
P-11.134 Risk factors for low graft function at 1 year after kidney transplantation
P-11.135 Artificial intelligence and machine learning to predict functional outcome of the arteriovenous fistulas - proof of concept model
Muhammad A Khurram, United Kingdom
P-11.136 Identification of driven risk factors for HLA-DR in kidney transplantation
Yunwei Zhang, Australia
P-11.137 Complete robotic-assisted kidney transplantation: A safe alternative to open approach
Seung Duk Lee, United States
P-11.139 Renal allograft outcome from hypertensive donor: Comparison between living and deceased donor
Yu Ho Lee, Korea
P-11.140 Comprehensive evaluation of echocardiographic changes after kidney transplantation and long-term outcomes
Camilo Cortesi, United States
P-11.141 Intra-patient tacrolimus level variability in BK virus associated nephropathy
Didem Turgut, Turkey
P-11.142 Intra-operative fluorescence angiography for renal graft perfusion assessment: An operative tool for post-transplant management
P-11.144 Comparison of rapamycin with cyclosporin, and tacrolimus in regards to the development of epithelial-to-mesenchymal transition (EMT) of tubular cells and endothelial-to-mesenchymal transition (EndoMT) of peritubular capillaries (PTCs)
Binnaz Handan Ozdemir, Turkey
P-11.145 Analysis of intra-patient variability of tacrolimus in transplant patients with data mining
Deniz DT Topcu, Turkey
P-11.146 Clinical benefits of coronary CT angiography in preventing cardiovascular complications among renal transplant recipients
Si Youn Kim, Korea
P-11.147 Sodium/glucose cotransporter 2 inhibitors reduce microalbuminuria in diabetic renal transplant patients.
Hyukyong Kwon, Korea
P-11.148 Effect of good dental care on oral inflammation, cytokines and chemokines levels in renal transplant patients: A randomized controlled study
Sonia Mehrotra, India
P-11.149 Angiotensin receptor blockers provide better glomerular filtration rates than angiotensin converting enzyme inhibitors in kidney transplant recipients with proteinuria
Burak Sayin, Turkey
P-11.150 Quality of life and associated factors of kidney transplant patients in Ethiopia
Mekdim Siyoum, Ethiopia
P-11.151 Study of donors weight and sex correlation with recipients graft function in living related renal transplant
Bhavin Satyanarayan Mandowara, India
P-11.152 Retroperitoneal viscum album extract injection in high drain output patient after renal transplantation
Youngjun Park, Korea
P-11.153 Assessment of middle ear mechanics, internal ear acoustical emission measurements and hearing in renal transplant recipients
Isilay Oz, Turkey
P-11.154 Survival and complications after multiple artery kidney transplantation
Emre Karakaya, Turkey
P-11.155 How calcineurin inhibitor dosage and blood trough levels affect kidney allograft survival?
Didem Turgut, Turkey
P-11.156 Why can’t I have a kidney transplant? Limitations to donate kidney or to have allograft
Zeynep Kendi Çelebi, Turkey
P-11.157 The new crescentic incision: A good option for donor nephrectomy
Ebru Hatice Ayvazoglu Soy, Turkey
P-11.159 Significance of rectal carriage screening for carbapenem resistance in a living donor renal transplantation setting in India
Sneha Haridas Anupama, India
P-11.161 Blood pressure levels depending on the differences in the levels of salt intake in kidney transplant recipients
P-11.164 Long term outcome of asymptomatic kidney transplantation recipients with chronotropic incompetence - A perspective study over 8 Years
Becky My Ma, Hong Kong
P-11.165 Evaluation of left ventricular geometric changes after kidney transplantation depending on allograft status
Camilo Cortesi, United States
P-11.166 Clinical features and sensitization risk factors in patients awaiting kidney transplantation: A single center experience
Zeynep Kendi Çelebi, Turkey
P-11.167 Prognostic value of early postoperative urinary protein to creatinine ratio after kidney transplantation
Hye Ryoun Jang, Korea
P-11.168 Does the Kidney Donor Profile Index (KDPI) predict graft and patient survival in our population? Experience of a transplant center in Argentina
Maria P. Dionisi, Argentina
P-11.169 Teriparatide in kidney transplant patients with severe hypocalcemia
Luis Roberto Leon, Argentina
P-11.171 The relationship between skeletal and mandibular/alveolar bone quality after solid organ transplantation
Bahar Füsun Oduncuoğlu, Turkey
P-11.173 Long term follow up of the orthopic renal transplant case with splenorenal anastomosis
Ebru Hatice Ayvazoglu Soy, Turkey
P-11.174 Erythrocytosis post renal transplantation: A single centre study
Mastakim Ahmed Mazumder, India
P-11.175 The change of frontal Qrs-t angle after renal transplantation in dialysis patients
Mustafa Yilmaz, Turkey
P-11.176 Survival analysis in the presence of competing risks in kidney transplant
Jessica J Pinto Ramirez PR, Colombia
P-11.177 Changes in ocular biometric parameters after renal transplantation
Leyla Asena, Turkey
P-11.179 Cystinosis in pediatric renal transplant recipients: Case control study from Kuwait
Osama Gheith, Kuwait
P-11.181 Paired kidney exchange transplantation experience in our center
Ebru Hatice Ayvazoglu Soy, Turkey
P-11.183 Evaluation of dental and periodontal health of renal transplant and hemodialysis patients
Bahar Füsun Oduncuoğlu, Turkey
P-11.184 Evolution of pediatric kidney transplantation: A single center experience
Vasiliy Bogdanov, Russian Federation
P-11.185 Factors associated with post-transplant anemia in Colombian population with kidney transplant between 2007-2015: A case control study
P-11.187 The influence of immediate graft blood flow on early graft function
Hsu-Han Wang, Taiwan
P-11.188 Is gastric sleeve surgery an optimal therapy for weight reduction post renal transplantation?
Fatima AlKindi, United Arab Emirates
P-11.190 IL-10 promotes chronic BK-virus infection and HLA class I antibody formation in renal transplant recipients
Rolf Weimer, Germany
P-11.192 A multidisciplinary approach in the management of enteric hyperoxaluria in kidney transplant candidates and recipients
Matthew R D'Costa, United States
P-11.193 Renal graft parenchyma qualitative assessment through fluorescence angiography before kidney transplantation
P-11.194 Pretransplant dialysis modality and long-term outcomes in kidney transplantation recipients: A propensity score matching analysis
Jin Hyuk Paek, Korea
P-11.195 Impact of body mass index and pre-sensitization in kidney transplant recipients on the long term allograft survival
Yohan Park, Korea
P-11.198 Predicting kidney function after high KDPI kidney transplantation: A comparison of expected vs. observed glomerular filtration rate in a large cohort of KDPI >85 kidney transplant recipients
Oscar K Serrano, United States
P-11.200 Kidney transplantation in pediatric patients with lower urinary tract dysfunction
Dorota Broniszczak-Czyszek, Poland
P-11.202 Preemptive kidney transplantation is associated with better graft survival compared with non‐preemptive transplantation.
Woo Yeong Park, Korea
P-11.204 Kidney graft survival is better in patients with normal body mass index
Leelo Järv, Estonia
Poster Session: Sex and Gender in Transplantation
P-15.06 Living donor kidney transplantation: Overcoming sex disparity in Japan
Mikiko Yoshikawa, Japan
P-15.01 Pregnancy outcomes in 1164 female kidney transplant recipients
Lisa Coscia, United States
P-15.04 Is altruistic (non-directed) living kidney donation a realm of Caucasian females? Experience from a single center in the United States
Amit Sharma, United States

WebApp Sponsor

© 2024 TTS 2020